Zacks small cap research.

Zacks Rank N/A A Precision Undertaking Zacks Small-Cap Research J Sponsored – Impartial – Comprehensive scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 September 13, 2022 ohn D. Vandermosten, CFA 312-265-9588 / [email protected] Revenue Q1 Q2 Q3 Q4 Year (Mar) (Jun) (Sep) (Dec) (Dec)

Zacks small cap research. Things To Know About Zacks small cap research.

When it comes to maintaining and enhancing the appearance of your vehicle, even the smallest details matter. One such detail that often goes overlooked is the wheel center caps. These small, circular covers not only add a touch of style to ...'Who needs breadth when we have Nvidia's beat?': We've been here before, and I can tell you it lasts longer than it should. Let's look at charts and indicators, past and present....NVDA We're in that part of the cycle wh...Qualigen Therapeutics, Inc. (NASDAQ:QLGN) is developing QN-165 (formerly AS1411) as a treatment for COVID-19. In October 2020, the company completed a positive pre-IND meeting with the U.S. FDA regarding QN-165’s development pathway. QN-165 is a DNA aptamer that has exhibited antiviral activity in multiple in vitro assays …Put on Your Rally Cap, as We Turn the Last Two Inside-Out Do you get the sense that folks were more bullish after last Wednesday's rally than they were after Monday's rally? That's the sense I get. I suppose that is because last week's rug ...

Novonix Cathode Materials is also expected to play a key role in the growing demand for batteries. Last month NVX launched a new pilot production facility for cathode materials in a new 35,000-square-foot facility. The facility enables Novonix to demonstrate the feasibility of large-scale production.

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …Zacks Premium Research for ZSCCX. Zacks MF Rank. More Info. This is our Mutual Fund rating system that serves as a timeliness indicator for Mutual Fund's over the next 6 months: Zacks Rank ...

By John Vandermosten, CFA NASDAQ:LTRN READ THE FULL LTRN RESEARCH REPORT While the clinical trial for LP-300 is ongoing in never-smoker, non-small cell lung cancer patients, Lantern Pharma, Inc. (NASDAQ:LTRN) has been busy advancing some of its earlier stage assets including LP-184 and LP-284. These small molecule acylfulvenes are chemically related as LP-284 is the positive enantiomer of LP-184.Apr 1, 2021 · By John Vandermosten, CFA NASDAQ:RVPH RP5063: Retroactive Comparison Against 32 Antipsychotics An estimated 0.25% to 1% of the global population suffers from schizophrenia. To address this estimated 20 million individuals with the chronic disorder there are numerous antipsychotics approved for use. However, a high discontinuation rate due to suboptimal efficacy and serious side effects reveals an SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …Sep 29, 2023 · By John Vandermosten, CFA NASDAQ:LTRN READ THE FULL LTRN RESEARCH REPORT While the clinical trial for LP-300 is ongoing in never-smoker, non-small cell lung cancer patients, Lantern Pharma, Inc. (NASDAQ:LTRN) has been busy advancing some of its earlier stage assets including LP-184 and LP-284. These small molecule acylfulvenes are chemically related as LP-284 is the positive enantiomer of LP-184. 'Who needs breadth when we have Nvidia's beat?': We've been here before, and I can tell you it lasts longer than it should. Let's look at charts and indicators, past and present....NVDA We're in that part of the cycle wh...

Zacks Equity Research December 04, 2023. Better trading ... Ahead of today’s normal trading session, only the small-cap Russell 2000 is in the green at this …

For the quarter ending September 30, 2022 and versus the same comparable prior year period: Research & development expenses totaled $702,000, falling 76% from $3.0 million on account of a reversal of amounts paid to a service provider and lower spending on LP-100. These movements were partially offset by recognition of expenses …

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …Financial Results. In its latest fiscal quarter ending December 31 st, IBS generated total revenues of $626,000 compared to $178,000 in the prior year period. 2Q:23 revenues included a component from both Intelligent Fingerprinting (IFP) and government support revenue while 2Q:22 revenues only included the government support component ...By M. Marin NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT Expect no disruption from management change; increased emphasis on studying Hemopurifier® in oncology likely… Aethlon Medical (NASDAQ:AEMD) appointed CFO James Frakes as interim CEO. We expect no disruption as a result of the management change – Mr. Frakes has been with Aethlon since 2008 knows the company well, in our view.By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Phase 1/2a Clinical Trials Underway for Pulmonary Disease Candidates In July 2022, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced the first subjects were dosed in two Phase 1/2a clinical trials of ARO-RAGE and ARO-MUC5AC, which are the company’s investigational candidates designed as potential treatmentsZacks Small Cap Research. TENX: Prioritizing Levosimendan. Read full article. Zacks Small Cap Research. May 22, 2023 at 6:44 AM ...

Giles Haycock Managing Director (T) 312.265.9351 (M) 312.752.6718 (F) 312.265.9560 (E) [email protected] Twitter: @ZacksSmallCap Steven Ralston, CFA Director of Research By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT Third Quarter Financial and Operational Review Tenax Therapeutics, Inc. (NASDAQ:TENX) reported 3Q:23 results on November 13, 2023 via its filing of Form 10-Q with the SEC. Since the filing of the second quarter 10-Q in mid-August, the company has finished compiling and submitting its investigational new drug (IND)Nov 16, 2023 · Net R&D expenses for the third quarter of 2023 were $3.3 million, compared to $3.8 million during the third quarter of 2022. The decrease was primarily due to decreased costs related to the Phase 3 clinical trial and decreased payroll expense, travel, materials, depreciation, and other activities. G&A expenses for the third quarter of 2023 were ... 3 Top-Ranked Beaten-Down Tech Stocks to Buy... AWS 10/6: Jobs Numbers Double to 336K on... PFP 10/6: All Eyes on This Morning's Jobs... Top Stock Reports for Alphabet, Sanofi &... A complete...Free Weekly Digest Zacks Small Cap Research covers more than 100 small- and micro-cap companies that are under-followed or under-valued by Wall Street. Our analysts cover all major sectors...

A conference call was also held to discuss results with investors. For the third quarter of 2023 ending September 30, 2023 and versus the prior year’s third quarter, no revenues were recognized. Net loss for the third quarter totaled ($73.5) million or ($4.89) per share. Operational expenses rose 67% over 3Q:23 levels as increases related to ...

By Brad Sorensen, CFA OTC:CLMEF READ THE FULL CLMEF RESEARCH REPORT We are reiterating are positive view on Calima Energy (OTC:CLMEF) and urging investors to take a look at a company with an in-demand asset that is well run, cares about shareholders, and is trading well below our conservative valuation of $0.55/share. …SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …19 May 2013 ... Zacks is a hoax. Top rated stocks become low rated stock very quickly. Out of approximately 20 top pick I had two that made money and all ...© Zacks Small Cap Research - All rights reserved Powered By Q4 Inc. 5.111.2.6 (opens in new window) 5.111.2.6 (opens in new window) By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Phase 1/2a Clinical Trials Underway for Pulmonary Disease Candidates In July 2022, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced the first subjects were dosed in two Phase 1/2a clinical trials of ARO-RAGE and ARO …Nov 15, 2023 · The NELL-1 technology is the centerpiece of what Bone Biologics (NASDAQ:BBLG) is developing. It was developed by UCLA TDG and Bone holds the exclusive worldwide rights to that technology. NELL-1 has been reviewed positively in over 45 peer reviewed publications demonstrating technological viability. NELL-1 has shown spine fusion effectiveness ... $30.59 USD -0.17 (-0.55%) Zacks MF Rank NA View All Zacks Mutual Fund Rank #1's Zacks Mutual Funds Categories » Small Cap Blend Latest Performance as of …Oct 17, 2022 · By Thomas Kerr, CFA NASDAQ:UXIN READ THE FULL UXIN RESEARCH REPORT Uxin Limited (NASDAQ:UXIN) operates a leading e-commerce platform for buying and selling used cars in China. The company also has two physical locations where customers can view and purchase cars in person. The company has recently transitioned to an inventory-owning model which provides customers with a comprehensive transaction Alpha-1062 Extended-Release Bioequivalence Study Topline Results. Results from the second bioequivalence study were shared with investors a few weeks ago on August 22, 2022. The data demonstrated pharmacokinetic equivalence between 5 mg of Alpha-1062 delayed release tablets and 8 mg galantamine hydrobromide extended …BSEM: BioStem Expands and Improves. BioStem Technologies, Inc. (OTC:BSEM) is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The company states its mission is “to discover, develop and produce the most ...

Nov 15, 2023 · The NELL-1 technology is the centerpiece of what Bone Biologics (NASDAQ:BBLG) is developing. It was developed by UCLA TDG and Bone holds the exclusive worldwide rights to that technology. NELL-1 has been reviewed positively in over 45 peer reviewed publications demonstrating technological viability. NELL-1 has shown spine fusion effectiveness ...

Genasys (. GNSS Quick Quote. GNSS - Free Report) has an Earnings ESP of +21.74% and a Zacks Rank #2. GNSS is scheduled to release fourth-quarter fiscal 2023 …

David Bautz, PhD, Senior Analyst for Zacks Small-Cap Research, with 9 years of direct experience in the securities and investment industry. David’s research articles have been posted extensively on Yahoo Finance News and throughout life sciences social media circles. Prior to joining Zacks in 2014, David was an NRSA postdoctoral fellow ... Zacks Rank N/A FRESH Results in November Zacks Small-Cap Research John D. Vandermosten, CFA Sponsored – Impartial – Comprehensive scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 September 6, 2022 312-265-9588 / [email protected] Our valuation uses a DCF model and a 15% discount rate. ItBy John Vandermosten, CFA NASDAQ:LTRN READ THE FULL LTRN RESEARCH REPORT While the clinical trial for LP-300 is ongoing in never-smoker, non-small cell lung cancer patients, Lantern Pharma, Inc. (NASDAQ:LTRN) has been busy advancing some of its earlier stage assets including LP-184 and LP-284. These small molecule acylfulvenes are chemically related as LP-284 is the positive enantiomer of LP-184.GBS: Glucose Biosensor Trial IRB Approval. 04/04/2022. Download (opens in new window) PDF 555 KBAchieve Life Sciences, Inc. (NASDAQ:ACHV) posted results from its Ongoing Research of Cytisinicline for Addiction, Vaping (ORCA-V1) trial and hosted a conference call for investors on April 20, 2023. The Phase II ORCA-V1 trial was conducted to measure the safety and effectiveness of 3 mg of cytisinicline dosed three times daily for 12 weeks ...Zacks Small-Cap Research Sponsored – Impartial - Comprehensive scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 August 24, 2021 John D. Vandermosten, CFA -265 9588 / [email protected] Second Quarter Update Based on our DCF model and a 15% discount rate, Reviva is valued at approximately $19.00 per share. Our model applies aJohn Vandermosten, CFA is currently a Senior Analyst for Zacks Investment Research where he covers a portfolio of small cap biotechnology names. His background includes 19 years of experience in a variety of investment management and research roles across all market cap ranges and throughout the capital structure. John is a frequent moderator ...Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE. _____ 1. BioLineRx Corporate Website, Accessed September 2023.Zacks Investment Research Page 4 scr.zacks.com The company has already presold the bulk of its 2023 capacity (and likely a significant portion of 2024 capacity) to customers and continues to announce customer wins with industry leaders in the energy storage market.Earnings Update. • Cash and cash equivalents were $1.5 million at the end of 3Q, down from $3.8 million at the end of 1Q. o During 3Q, Ensysce (NASDAQ:ENSC) completed a convertible note financing offer that netted the company roughly $560,000 before fees and offering expenses, with the potential for another $1.13 million upon “satisfaction ...By John Vandermosten, CFA NASDAQ:RVPH RP5063: Retroactive Comparison Against 32 Antipsychotics An estimated 0.25% to 1% of the global population suffers from schizophrenia. To address this estimated 20 million individuals with the chronic disorder there are numerous antipsychotics approved for use. However, a high discontinuation rate due to suboptimal efficacy and serious side effects reveals an

Gain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap Research. BETHESDA, Md., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Gain …Jan 13, 2023 · By Lisa Thompson OTC:NEXCF READ THE FULL NEXCF RESEARCH REPORT Yesterday Nextech (OTC:NEXCF) preannounced preliminary 2022 revenues of $10.3 million for the year or $1.4 million for Q4 2022. While this looks like a miss compared to our model, it includes $958,822 in revenues eliminated from historical product sales booked in Q1 and Q2 due to reclassifying the pet business as a discontinued Gain Therapeutics, Inc. today announced that the Company’s Chief Executive Officer, Matthias Alder, will participate in a fireside chat, hosted by FORCE Family Office, …Zacks Rank N/A FY21 Results; IO Revenues Analysis Zacks Small-Cap Research John D. Vandermosten, CFA Sponsored – Impartial – Comprehensive scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 January 11, 2022 312-265-9588 / [email protected] Revenue Q1 Q2 Q3 Q4 Year (Dec) (Mar) (Jun) (Sep) (Sep)Instagram:https://instagram. wms stocksafpcapitalold quarter coinshow do i buy stock directly from a company The following disclosures relate to relationships between Zacks Small-Cap Research ( Zacks SCR ), a division of Zacks Investment Research ( ZIR ), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe. ANALYST DISCLOSURES. Zacks SCR Analysts hereby certify that the view expressed in this research report or article ...A conference call with investors and analysts was held immediately following the release. 2Q:23 revenues of $3.6 million were ahead of our initial estimates and matched revised company guidance. Net loss per share was ($1.03). Management reiterated its outlook of revenues between $14.0 and $15.0 million in 2023. houston financial advisorsbest platform to buy shiba inu Q4 2022 gross margin increased to 30.9% from 24.3% a year ago and 29.2% in Q3 2022. The increase was primarily from the elimination of $20 million of low-margin revenues from the closure of the Japanese fab which were replaced by higher-margin sales generated from outside customers. Gross margin dollars increased by $25 million, or 25%.Zacks Small Cap Research Coverage Universe. For access to our most recent reports, please click on the links below. To join our paid real time email service please enter your email address and select the companies you would like to follow. An email will be sent to you for payment and setup instructions. Special Situations / Steven Ralston, CFA. stock trading bot software By John Vandermosten, CFA NASDAQ:RVPH READ THE FULL RVPH RESEARCH REPORT Fourth Quarter and Fiscal Year 2021 Financial and Operational Results On March 15, 2022, Reviva Pharmaceutical Holdings, Inc. (NASDAQ:RVPH) announced fourth quarter and fiscal year 2021 financial and operational results and filed …16 Feb 2022 ... With Sharesight, investors can get Zacks Investment Research news directly in their portfolio for US stocks. ... Small Caps and ausbiz. Sharesight ...$31.77 USD -0.10 (-0.31%) Zacks MF Rank NA View All Zacks Mutual Fund Rank #1's Zacks Mutual Funds Categories » Small Cap Blend Latest Performance as of Oct 31, 2023 * Annual for three...